Cefuroxime Axetil Tablets

This product is a second-generation cephalosporin antibiotic. After oral absorption through the gastrointestinal tract, it is rapidly hydrolyzed into cefuroxime under the action of esterase to exert its antibacterial effect. The activity against Gram-positive cocci is similar to or slightly worse than that of the first-generation cephalosporins, but it is quite stable against the b-lactamase produced by Staphylococci and Gram-negative bacilli. Except for methicillin-resistant Staphylococci, Enterococci and Listeria, other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity of this product against Staphylococcus aureus is worse than that of cefazolin. 1-2 mg/L of this product can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, Escherichia coli, Proteus mirabilis, etc. are sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, most Serratia are resistant, Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

The main ingredient of this product is cefuroxime axetil, whose chemical name is (6R,7R)-7-[2-furanyl(methoxyimino)acetylamino]-3-carbamoyloxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 1-acetoxyethyl ester.

This product is a film-coated tablet, which appears off-white after removing the coating.

This product is suitable for acute pharyngitis or tonsillitis in adults, acute otitis media, maxillary sinusitis, acute exacerbation of chronic bronchitis, acute bronchitis, simple urinary tract infection, skin and soft tissue infection, and uncomplicated gonorrhea Neisseria urethritis and cervicitis caused by sensitive strains of Enterobacteriaceae such as hemolytic streptococci, Staphylococcus aureus (except methicillin-resistant strains), Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. It is also suitable for pharyngitis or tonsillitis, acute otitis media, and impetigo in children.

Oral administration: Adults: For mild and moderate lower respiratory tract infections (or general infections), 0.25g/time, twice a day. For severe respiratory tract infections, 0.5g/time, twice a day. For simple urinary tract infections, 0.125g/time, twice a day. For simple gonorrhea, 1g/time, twice a day. For pyelonephritis, the recommended dose is 0.25g/time, twice a day. Children: Generally 0.125g to 0.25g per day, twice a day. For children over two years old with otitis media, 0.25g/time, twice a day (not to exceed 0.5g per day).

1. Common gastrointestinal reactions include diarrhea, nausea and vomiting. 2. Rare allergic reactions include rash and drug fever. 3. Occasionally, pseudomembranous colitis, eosinophilia, increased blood bilirubin, decreased hemoglobin, changes in renal function, positive Coombs test and transient increase in liver enzymes are seen.

1. It is contraindicated for patients who are allergic to this product and other cephalosporins, those with a history of anaphylactic shock or immediate reaction to penicillin, and those with gastrointestinal absorption disorders. 2. It is contraindicated for children under 5 years old.

Precautions for children: This product is contraindicated for children under 5 years old. Cefuroxime axetil suspension is recommended. Precautions for pregnancy and lactation: 1. No evidence of harm to the fetus was found in animal experiments, but there is a lack of sufficient information in human studies. Therefore, pregnant women should use this product with caution only when there is a clear indication. 2. This product can be excreted through breast milk, so lactating women should use it with caution or stop breastfeeding. This product is contraindicated for children under 5 years old. Cefuroxime axetil suspension is recommended. Precautions for the elderly: The blood elimination half-life (t1/2β) of elderly patients (average age 84 years old) can be extended to about 3.5 hours. Therefore, the dosage or medication interval should be adjusted according to the renal function under the guidance of a doctor.

1. The combined use of strong diuretics such as furosemide, ethacrynic acid, bumetanide, anti-tumor drugs such as carmustine, streptozocin, and nephrotoxic drugs such as aminoglycoside antibiotics with this product may increase nephrotoxicity. 2. Clavulanic acid can enhance the antibacterial activity of this product against certain Gram-negative bacteria that are resistant to this product due to the production of beta-lactamase. 3. The combined use of this product with probenecid can increase the area under the drug-time curve (AUC value) of this product by about 50%. 4. The combined use of this product with antacids can reduce the absorption of this product.

Protect from light, seal tightly and store in a cool place.

0.125g

24 months.

NCPC Hebei HUAMIN Pharmaceutical Co., Ltd.

• Founded in:

  2010-04-28

• Address:

  No. 98, Hainan Road, Shijiazhuang Economic and Technological Development Zone

• Tax NO.:

  91130182554463533P

• Registered Funds:

  1.450139 million yuan

• Website:

  Log in to view

• Email:

  Log in to view